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haematologist, included the following domains: reliance on
transfusions/health care providers; arranging life around medical
appointments; fatigue limiting routine physical activities; disease
interference with social and family life; worry about the future
due to health condition; discomfort; reliance on support for self
care and routine activities; feelings of being a burden to family;
and feeling sad, hopeless, and helpless. Face-to-face interviews
used the Feeling Thermometer VAS and the TTO method to
value the HS on a 0 (dead) to 1 (perfect health) scale. Socio-
demographic, clinical, and quality-of-life (EQ-5D) characteristics
were surveyed. RESULTS: The mean age was 67 y (range:
29–83); 45% male, 70% retired; 40% had secondary/high school
education, or higher (32%), and 79% lived with family, a partner
or spouse, or friends. The mean time from MDS diagnosis was 5
years (range: 1–23). Most patients (87%) received previous
transfusions and 49% had received a transfusion in the last 3
months. Mean utility score was 0.78; patients reported at least
some problem with mobility (45%), usual activities (40%), pain/
discomfort (47%), and anxiety/depression (34%). Few patients
had difﬁculty understanding the VAS (n = 3) and TTO (n = 4)
exercises. Utility scores for TI were higher than for RT (0.84 vs.
0.77; p = 0.06) or TD (0.84 vs. 0.60; p < 0.001). Three patients
rated TD worse than dead. Corresponding VAS scale scores were
78 vs. 56; (p < 0.001), and 78 vs. 31 (p < 0.001), respectively.
CONCLUSION: Patients value TI, suggesting an important role
for new treatments aiming to achieve greater TI in MDS.
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OBJECTIVES: Chronic iron overload due to frequent blood
transfusions is a condition affecting patients with a wide range of
disorders including beta-thalassaemia, sickle cell disease and
myelodysplastic syndromes. A UK community based utility study
was conducted to value preferences for iron chelation therapy
(ICT) administered via two different modes of administration:
once daily oral administration (deferasirox) and slow subcutane-
ous infusion for 8–12 hours per day, 5–7 days/week (current
standard treatment desferrioxamine). METHODS: Time trade
off (TTO) methods were used to value health states for oral and
subcutaneous modes of ICT administration. An anchor descrip-
tion for the reference condition, beta-thalassaemia, was incorpo-
rated within each health state. The descriptions were validated by
5 UK clinicians. Neither health state made reference to the asso-
ciated drug name. Mean utilities were estimated and 95% con-
ﬁdence intervals calculated using bootstrapping sampling and
estimation. The Wilcoxon Signed-Rank Test was used to test
signiﬁcant differences between the health state mean utility
values. RESULTS: A representative cross sectional sample of 120
respondents from the UK population participated in the TTO
exercise. Analysis was performed for 115 respondents (5
responses were excluded due to lack of understanding of the
exercise). 54% were female, 76% aged 21–60 years. Mean utility
for the oral ICT health state was 0.84 (SD: 0.17) compared to
0.66 (SD: 0.21) for the subcutaneous infusion ICT health state.
There was a mean difference of 0.17 (95% CI: 0.147, 0.214) in
utility values between the health states (p < 0.0001). The utility
results are consistent with those from a similarly designed Aus-
tralian study. CONCLUSION: From a societal perspective the
utility beneﬁt associated with once daily oral ICT for chronic
iron overload is signiﬁcantly greater relative to current standard
subcutaneous treatment. This data can be used in cost-utility
analyses comparing oral Deferasirox and current standard care
desferrioxamine.
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OBJECTIVES: The aim of this study was to provide insights into
the experiences, behavior and attitudes of patients towards
controlled ovarian stimulation (COS). METHODS: A cross-
sectional explorative study involving semi-structured in-depth
interviews, including a laddering technique (means–end relation
theory) to link treatment characteristics to emotional drivers. A
total of 190 women (age 25–40) in France, Germany, Italy,
Japan, Spain, Turkey, UK and USA who completed an IVF cycle
in the last 6 months were randomly allocated via general popu-
lation databases. RESULTS: When asked about their experiences
during the COS phase 31% of patients mentioned that COS
limited their daily activities because they wanted to be home at
speciﬁc times for the injections and 19% described the schedule
as stressful or emotionally demanding. Most mentioned incon-
veniences regarding injections were timing of injections, injection
site pain and the hassle with syringes and vials. In spite of
education and training on injections, 59% of women were con-
cerned about incorrect injections. In total 45% of women expe-
rienced difﬁculties, like injecting at the wrong time, incorrect
dosing, hitting a vessel or fear of self-injection. Having realized
they had made a mistake, 68% felt worried or stressed about it
and 13% were anxious that it would have a negative impact on
treatment outcome. When asked women said that daily injection
regimens could be improved by pen or oral administration, by
pre-mixed ready-for-use methods and by reducing the number of
injections. This would reduce the worries and stress associated
with COS and 40% of subjects stated to believe that this would
improve their emotional well-being and increase their chance of
a baby. CONCLUSION: COS has serious emotional and psycho-
logical impact on patients undergoing IVF. According to women
simple and short treatment regimen with less concern about
correct administration will improve their emotional well-being
during COS.
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OBJECTIVES: The management of hemophilia when patients
develop inhibitors is particularly complex and costly. Although
the advances of modern technologies, no agreement still exists on
how to optimally treat these patients. Treatment of haemophilia
is result of interactions between patients, physicians, pharmacists
and budget holders, each carrying their own set of preferences.
This study was conducted to evaluate preferences toward pos-
sible coagulation factor concentrates used in patients with inhibi-
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